Navigation Links
EAU launches new clinical guidelines for 2009 -- kidney cancer
Date:3/17/2009

Arnhem, The Netherlands A number of updated guidelines will be presented at the 24th Annual Congress of the European Association of Urology (EAU) held in Stockholm, from 17 though 21 March. The abridged versions - Pocket Guidelines which are based on the extended text documents will also be available in Stockholm to all EAU members and press.

Production of clinical guidelines is one of the core activities of the organisation. Close to 150 experts split up over 18 different topic-oriented panels, are involved in this ongoing process. Guidelines aim to present the best evidence available on a given pathology and provide a standardized approach to the treatment of urological conditions. Ultimately, healthcare professionals must make their own decisions about care on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge and expertise.

Kidney Cancer

Due to the enhanced use of imaging techniques over the past years a stage shift has been seen in the field of renal cell cancer with a volume increase in the incidental detection of smaller cancers (< 4 cm). Thirty percent of these findings are benign. The treatment of metastatic small tumours show a decrease in death rates. A considerable portion of these tumours can be treated with nephron sparing surgery. Additionally, a number of targeted agents have become available with several more expected shortly.

The panel updated these Kidney Cancer guidelines since for several targeted agents more mature data have been published and validated prognostic nomograms predicting treatment outcome accuracy are available for more treatment options.

The panel do not recommend Interferon-alpha (IFN-alpha) in a first-line setting as monotherapy in the treatment of metastatic RCC. Sunitinib and Bevacizumab + IFN-alpha are recommended as first-line therapy in low- and intermediate-risk patients while

Temsirolimus is recommended for high risk patients; Sorafenib and Everolimus can be recommended as second-line therapy after cytokine and tyrosine kinase inhibitor (TKI) failure, respectively.

The expectation is that further targeted agents will be on the market shortly. Also the role of molecular medicine in the treatment of renal cell carcinoma will become more prominent. A subsequent update will take this information in, once sufficiently data is available.

The panel consists of an expert group chaired by B. Ljungberg and includes D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard and I.C. Sinescu.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. MIT scientist launches special nanoscience symposia at ACS National Meeting
2. ESA launches first Earth Explorer mission GOCE
3. HRSA Launches Online Resource to Help Prevent Poisonings
4. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
5. Cardinal Health Launches New Products for the Operating Room
6. GeoFitness Launches Get Moving America Campaign to Improve Youth Health
7. Health Integrated Launches Unique Service for Health Plans Preparing for Federal Mental Health Parity Regulations
8. Confidential Listening Service We Just Listen Launches, Providing Americans a Private Platform to Express Their Thoughts and Feelings
9. eCardio Diagnostics Launches Academic Medicine Initiative
10. MorseLife Launches Learning Institute to Teach Best Practices in Leadership, Healthcare and Kosher Culinary
11. ADA Launches Community Dental Health Coordinator Program to Provide Dental Care in Underserved Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: